Navigation Links
Jennerex Announces Presentations at Upcoming Conferences
Date:12/23/2009

SAN FRANCISCO, Dec. 23 /PRNewswire/ -- Jennerex Biotherapeutics, a clinical-stage biotherapeutics company developing a proprietary breakthrough class of targeted oncolytic virus therapeutics, today announced that management will present at the following upcoming investor conferences.


    Biotech Showcase 2010
    Tuesday, January 12, 2010
    9:40 a.m. PT
    Marines' Memorial Club and Hotel, San Francisco

    OneMedForum 2010
    Wednesday, January 13, 2010
    2:40 p.m. PT
    Sir Francis Drake Hotel, San Francisco

About Jennerex

Jennerex is a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The Company's lead product JX-594, currently in an international randomized Phase 2 clinical trial for patients with primary liver cancer, demonstrated promising Phase 1 efficacy and safety results in patients with a diverse array of common cancers. Jennerex's products target, attack and eradicate cancers through a novel and potent oncolytic mechanism that is dependent on highly-specific replication of the Company's poxviruses in cancer cells. These products not only cause cancer cell lysis thereby killing through replication, they simultaneously shut-off the blood supply to tumors, as well as stimulating the body's immune response to the cancer. Jennerex, Inc. is headquartered in San Francisco and has manufacturing and research activities based at the Ottawa Hospital Research Institute in Ottawa, Canada. For more information about Jennerex and the Company's pipeline of three clinical-stage products, please visit www.jennerex.com .

SOURCE Jennerex Biotherapeutics


'/>"/>
SOURCE Jennerex Biotherapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Jennerex, Inc. Receives EMEA Orphan Drug Designation for JX-594 for the Treatment of Hepatocellular Carcinoma
2. Jennerex Therapeutic Research Collaboration With Ottawa Hospital Research Institute Selected for $10 Million Grant From Ontario Institute for Cancer Research
3. Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer
4. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
5. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
6. Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
7. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
8. Macomb County Announces Final 2009 H1N1 Clinic
9. Access MediQuip Announces Release of Partners in Focus Provider Portal
10. Unilens Announces Extraordinary Meeting Results
11. Arrayit Corporation Announces Manufacturing Breakthrough
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... NEW YORK , May 2, 2016 /PRNewswire/ ... Series B financing of Graybug Vision, Inc. Graybug ... to developing therapies that may transform care for ... and glaucoma.  Graybug Vision,s technology was first developed ... out into a startup venture. ...
(Date:4/29/2016)... 2016  In the next ten years, the ... systems dependent on CRTs monitors to those reliant on ... Medical monitors and will automatically sync to existing ... foreseeable benefits to this technological advancement, it also ... to be replaced in order to be LCD ...
(Date:4/29/2016)... -- Glycotope GmbH, a clinical-stage immuno-oncology company ... of Dr. Alfredo Zurlo as Chief Medical ... many years clinical experience and a proven track record ... was at Mologen AG where he was Chief Medical ... Zurlo held various positions at F Hoffmann La Roche ...
Breaking Medicine Technology:
(Date:5/2/2016)... ... May 02, 2016 , ... “Engineering Bubbles,” an oil painting submitted ... ARRS Art Forum held recently at the Annual Meeting in Los Angeles. The first ... ARRS members and Annual Meeting attendees. , “Through art I hope to ...
(Date:5/2/2016)... ... May 02, 2016 , ... Over $60 Billion is spent ... pet gear and toys, leading product review site for Toys, Tots, Pets & More ... at their Spring Showcase at the Metropolitan Pavilion in New York City. , ...
(Date:5/2/2016)... , ... May 02, 2016 , ... ... has announced a new Specialty Pharmacy Patient Satisfaction Award that will recognize specialty ... the quarterly results from Zitter Health Insights’ Specialty Pharmacy Patient Satisfaction Survey compiled ...
(Date:5/2/2016)... ... ... According to an American Psychological Association article, the Centers for Disease ... of 18. Of those who survive, many still face effects as they reach adulthood. ... new book, Lyah! Lyah! Pants on Fyah!, she shares stories from women who are ...
(Date:5/2/2016)... (PRWEB) , ... May 02, 2016 , ... ... Research & Analytics EVP and GM Jim Callandrillo and Duane Reed, VP ... 55th Annual Pharmaceutical Business Intelligence and Research Group (PBIRG) General Meeting ...
Breaking Medicine News(10 mins):